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STUDY QUESTION:What is the clinical-effectiveness and safety of the endometrial scratch (ES) procedure compared to no ES, prior to
usual first time in vitro fertilisation (IVF) treatment?
SUMMARY ANSWER: ES was safe but did not improve pregnancy outcomes when performed in the mid-luteal phase prior to the first
IVF cycle, with or without intracytoplasmic sperm injection (ICSI).
WHAT IS KNOWN ALREADY: ES is an ‘add-on’ treatment that is available to women undergoing a first cycle of IVF, with or without
ICSI, despite a lack of evidence to support its use.
STUDY DESIGN, SIZE, DURATION: This pragmatic, superiority, open-label, multi-centre, parallel-group randomised controlled trial
involving 1048 women assessed the clinical effectiveness and safety of the ES procedure prior to first time IVF, with or without ICSI,
between July 2016 and October 2019.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Participants aged 18–37 years undergoing their first cycle of IVF, with or
without ICSI, were recruited from 16 UK fertility clinics and randomised (1:1) by a web-based system with restricted access rights that
concealed allocation. Stratified block randomisation was used to allocate participants to TAU or ES in the mid-luteal phase followed by
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usual IVF with or without ICSI treatment. The primary outcome was live birth after completing 24weeks gestation within 10.5months of
egg collection.
MAIN RESULTS AND THE ROLE OF CHANCE: In total, 1048 women randomised to TAU (n¼ 525) and ES (n¼ 523) were available
for intention to treat analysis. In the ES group, 453 (86.6%) received the ES procedure. IVF, with or without ICSI, was received in
494 (94.1%) and 497 (95.0%) of ES and TAU participants respectively. Live birth rate was 37.1% (195/525) in the TAU and 38.6%
(202/523) in the ES: an unadjusted absolute difference of 1.5% (95% CI 4.4% to 7.4%, P¼ 0.621). There were no statistical differences
in secondary outcomes. Adverse events were comparable across groups.
LIMITATIONS, REASONS FOR CAUTION: A sham ES procedure was not undertaken in the control group, however, we do not
believe this would have influenced the results as objective fertility outcomes were used.
WIDER IMPLICATIONS OF THE FINDINGS: This is the largest trial that is adequately powered to assess the impact of ES on women
undergoing their first cycle of IVF. ES was safe, but did not significantly improve pregnancy outcomes when performed in the mid-luteal
phase prior to the first IVF or ICSI cycle. We recommend that ES is not undertaken in this population.
STUDY FUNDING/COMPETING INTEREST(S): Funded by the National Institute of Health Research. Stephen Walters is an National
Institute for Health Research (NIHR) Senior Investigator (2018 to present) and was a member of the following during the project: National
Institute for Health Research (NIHR) Health Technology Assessment (HTA) Clinical Trials and Evaluation Committee (2011–2017), NIHR
HTA Commissioning Strategy Group (2012 to 2017); NIHR Programme Grants for Applied Research Committee (2020 to present); NIHR
Pre doctoral Fellowship Committee (2019 to present). Dr. Martins da Silva reports grants from AstraZeneca, during the conduct of the
study; and is Associate editor of Human Reproduction and Editorial Board member of Reproduction and Fertility. Dr. Bhide reports grants
from Bart’s Charity and grants and non-financial support from Pharmasure Pharmaceuticals outside the submitted work.
TRIAL REGISTRATION NUMBER: ISRCTN number: ISRCTN23800982.
TRIAL REGISTRATION DATE: 31 May 2016
DATE OF FIRST PATIENT’S ENROLMENT: 04 July 2016
Key words: endometrial scratch / assisted reproduction / IVF / live birth / randomised controlled trial
Introduction
IVF and ICSI are widely used assisted reproductive technologies
(ARTs) for women who are unable to conceive naturally. Success rates
are modest, with an overall live birth rate (LBR) of 27% in the UK,
with some evidence to suggest that worldwide success rates have been
decreasing over recent years (Gleicher et al., 2019). In an attempt to
increase their chances of success, couples undergoing IVF or ICSI can
select from a bewildering choice of ‘add-ons’, most of which lack evi-
dence to support their benefits (Macklon et al., 2019; Wise, 2019).
One such add-on is the endometrial scratch (ES) procedure, which
involves endometrial biopsy (‘scratching’) with a pipelle or similar sam-
pling device. Because ES was first recognised as a potential intervention
to increase the chance of implantation (Barash et al., 2003), several bi-
ological hypotheses for a beneficial effect caused by inducing mechani-
cal endometrial trauma have been suggested such as the release of
inflammatory mediators, modulation of endometrial genes involved in
membrane stability and enhancement of endometrial angiogenesis
(Kalma et al., 2009; Gnainsky et al., 2010; Yang et al., 2019).
Previous studies have examined the role of ES in various infertile
populations but have focussed mainly on the recurrent implantation
population (Raziel et al., 2007; Huang et al., 2011; El-Toukhy et al.,
2012). There have not been any high-quality randomised controlled
trials (RCTs) adequately powered to assess the effectiveness of ES in
women undergoing their first cycle of IVF/ICSI despite the use of
the procedure in this particular population in clinical practice. Several
controlled trials have identified contradictory evidence, with a 2019
systematic review by Vitagliano et al. (2019) identifying insufficient
evidence to support the benefits of ES, concluding that an effect could
not be ruled out. Many of these previous studies included heteroge-
neous patients, including both women undergoing their first IVF cycle,
and women undergoing subsequent cycles, and were therefore not
powered to detect clinically worthwhile effects in those undergoing
their first IVF cycle (Nastri et al., 2013; Yeung et al., 2014; Lensen
et al., 2019; Mackens et al., 2020). The two largest trials to focus spe-
cifically on women undergoing their first cycle of IVF included 418 and
300 participants and found significant increases in IVF success in
women that received ES (Mahran et al., 2016; Maged et al., 2018) but,
according to the Vitagliano et al. review, the risk of bias was deemed
to be high in one study (Mahran et al., 2016), and the other did not
follow-up participants until delivery (Maged et al., 2018; Vitagliano
et al., 2019). A high-quality RCT is required to definitively conclude if
the ES procedure is effective and safe (Vitagliano et al., 2019).
Despite the lack of evidence, ES is still provided to some women
undergoing their first cycle of IVF with or without ICSI in fertility
centres internationally (Lensen et al., 2016). This definitive RCT
assessed the clinical effectiveness and safety of the ES procedure com-
pared to treatment as usual (TAU) in women undergoing their first
IVF cycle, with or without ICSI.
Materials and methods
Trial design and oversight
We conducted a randomised, two-arm, superiority, open-label,
parallel-group multicentre clinical trial, at 16 fertility units in the UK,
two of which were run privately. The trial was designed to be
















































































































































































































































pragmatic on the basis of PRECIS-2 criteria (Supplementary Table SI;
Loudon et al., 2015). The original trial protocol has been published
previously (Pye et al., 2018) and the latest protocol with amendments
is accessible (Metwally et al., 2020). A list of protocol amendments,
with reasons, can be found in Supplementary Table SII.
Independent Trial Steering and Data Monitoring and Ethics
Committees (TSC/DMEC) provided trial oversight. The trial had no
interim analyses but the DMEC reviewed unblinded safety and out-
come data every 6months. A 6-month internal pilot assessed the fea-
sibility of the trial. The trial was funded by the National Institute for
Health Research (NIHR HTA 14/08/45), who had no role in the
design, conduct, analysis or reporting of the trial. Ethics approval
was granted by South Central Berkshire Research Ethics Committee
(16/SC/0151) and the trial was registered with ISRCTN
(ISRCTN23800982). The authors assume responsibility for the accu-
racy and completeness of the data and analyses, as well as adherence
to the protocol and interpretation of results.
Participants
Participants were women aged 18–37 years (inclusive); were undergo-
ing their first cycle of IVF, with or without ICSI; were expected to be
using fresh embryos and a single embryo transfer (SET); had a regular
ovulatory menstrual cycle defined by clinical judgement or with ovula-
tory levels of midluteal serum progesterone, normal uterine cavity
assessed by transvaginal sonography at screening, with no endometrial
abnormalities that would require treatment to facilitate pregnancy
(such as suspected intrauterine adhesions, uterine septae, submucosal
fibroids or intramural fibroids exceeding 4 cm in diameter), good ovar-
ian reserve assessed clinically, biochemically (FSH < 10 UI/L) and nor-
mal follicular phase oestradiol levels and/or normal anti-Müllerian
hormone levels or sonographically (antral follicle count) and no history
of previous radiotherapy or chemotherapy; had no relevant vaginal/
uterine infections; and, if randomised to receive ES, were willing to use
a barrier method of contraception prior to the procedure if necessary.
Participants were excluded if they had received previous trauma to the
endometrium (resection of uterine septum, intrauterine adhesions, or
recent resection of significant submucous fibroids), had a BMI of
35 Kg/m2 or greater, were participating in another interventional fertil-
ity study, or had grade 4 endometriosis. All laboratory or ultrasound
standards were based on local reference ranges. From July 2017, the
eligibility criteria were altered so that participants undergoing ultra-long
protocols were excluded, the use of which is commonly associated
with severe endometriosis which may have an adverse effect on im-
plantation and hence may have a confounding effect on the results.
Those having other endometrial procedures (e.g. endometrial biopsy
for the collection of natural killer cells) were also excluded.
Trial procedures
Following informed consent, baseline assessments were undertaken
prior to randomisation. Individuals were informed that participation in
the trial may delay the start of their IVF cycle, if randomisation was be-
ing undertaken close to the start of their treatment. IVF was only
delayed where necessary, with the agreement of both the patient and
fertility team, in order to allow the ES to be scheduled prior to IVF.
At a timepoint between the participant’s initial IVF clinic consultation
and the start of their IVF cycle, participants were randomly assigned
(1:1) to the intervention or control arms by a doctor or nurse at the
fertility unit using a web-based randomisation system with restricted
access rights that concealed allocation. The trial statistician generated
the randomisation sequence using a computer via a web-based system,
but the access rights of the randomisation system did not allow this in-
dividual, or the research staff, to access the generated randomisation
sequence. Stratified block randomisation was used, with randomly
permuted blocks of sizes 2, 4, and 6 stratified by site and planned
IVF/ICSI (antagonist or long). Block sizes were masked to the research
team except for the trial statistician who was not involved in the
screening and randomisation process. The trial statisticians and health
economist were blinded and did not have access to patient level
data during the trial, but blinding of site staff or participants was not
possible owing to the nature of the intervention. Another statistician
responsible for preparing unblinded summaries for the DMEC had no
role in the day-to-day conduct of the trial.
Those allocated to the intervention arm received the ES procedure,
which was undertaken in the mid-luteal phase (defined as 5–7days be-
fore the expected next period, or 7–9 days after a positive ovulation
test) of the menstrual cycle preceding IVF/ICSI by a suitably qualified
doctor or nurse. Participants were required to use a barrier method
of contraception (if necessary) in the menstrual cycle in which the
ES was performed. ES was performed by inserting a speculum into the
vagina and the cervix was exposed and cleaned. A pipelle sampler or
similar device was then inserted into the cavity of the uterus and nega-
tive pressure was applied by withdrawal of the plunger. The sampler
was then rotated and withdrawn 3 to 4 times so that tissue appeared
in the transparent tube. The sampler and speculum were then re-
moved. Pain ratings and tolerability were then collected from the
patient.
Participants randomised to the control arm (TAU) received IVF
treatment, with or without ICSI, in line with the usual care practice of
their fertility unit. Those randomised to the ES arm received usual IVF
treatment, with or without ICSI, in the menstrual cycle after the ES
procedure.
Participants were followed up via telephone by a member of the
research team based at the fertility unit for up to 10.5months post
egg collection. This time frame was selected to allow for any resulting
pregnancy to reach full-term to observe a live birth outcome and
6weeks postpartum follow-up of babies born. Egg collection was
used as the starting point of the follow-up time frame rather than
randomisation to standardise follow-up across treatment groups, as
participants in the ES were expected to have a delay in the start of
their IVF cycle after randomisation to allow ES to take place.
Participants were not followed up if they were discontinued from the
trial (pregnancy not achieved following first embryo transfer, end of
pregnancy, investigator decision), withdrew or were lost to follow-up
(Supplementary Fig. S4). For all participants, details of the IVF/ICSI
treatments received and their initial outcome (e.g. the number of eggs
collected, quality of embryos transferred, implantation, and pregnancy)
were collected from the patient’s medical records. Following a positive
pregnancy test, follow-up was undertaken via telephone at 3 and
6months post egg collection and 6weeks post-partum to collect
pregnancy-related outcomes and adverse events (AEs). Participants who
became pregnant naturally prior to their first embryo transfer were fol-
lowed up for the duration of their pregnancy. In case of cycles where all
embryos had been frozen, or where the start of IVF had been delayed,
















































































































































































































































the outcome of the first embryo transfer was collected if it had oc-
curred within the overall study data collection period: The outcomes of
such pregnancies were collected from the participant’s medical notes in
order to minimise missing data on the primary outcome.
Outcomes
The primary outcome was live birth (defined as live birth after comple-
tion of 24weeks gestation). The secondary outcomes were implanta-
tion (based on a positive serum beta-hCG on approximately day 14
following egg collection, or by a positive urine pregnancy test), clinical
pregnancy (an observation of viable intrauterine pregnancy with a posi-
tive heart pulsation seen on ultrasound at/after 8weeks gestation),
miscarriage (as measured by spontaneous pregnancy loss, including
pregnancy of unknown location prior to 24weeks gestation, within the
10.5month post egg collection follow-up period), ectopic pregnancy
(as measured by the rate of pregnancy outside the normal uterine cav-
ity), multiple birth (defined as the birth of more than one living foetus
after completed 24weeks gestation), preterm delivery (as measured
by live birth after 24weeks and before 37weeks gestation within the
10.5month post egg collection follow-up period), stillbirth (based on
the delivery of a stillborn foetus showing no signs of life after 24weeks
gestation within the 10.5month post egg collection follow-up period),
and details of the participant’s IVF cycle, including number of eggs re-
trieved and number of embryos generated. The quality of embryos
transferred was assessed by an embryologist using grading systems as
presented in Supplementary Tables SIII and SIV.
For those participants who received the ES, tolerability of the proce-
dure (yes/no) and post-procedure pain (using a Likert scale between
0 and 10 collected within 30minutes of the ES, and at 1 day and 7 days
post ES) were recorded.
Safety outcomes were collected for the duration of participation in
the trial and included any untoward medical event in the mother and,
in the baby, neonatal death or a severe congenital abnormality [de-
fined as an abnormality not listed on the European Surveillance of
Congenital Anomalies (EUROCAT) minor anomalies list (EUROCAT,
2013)] up to 6weeks post-partum. Expectedness was assessed for all
events, with a list of expected events pre-specified in the protocol as
either expected AEs, or expected serious adverse events (SAEs).
Expected events were those that were considered to be expected
during pregnancy or an IVF cycle (e.g. expected AEs included nausea,
hot flushes; expected SAEs included hospitalisation for rest or gesta-
tional diabetes). Any event reported that was not on the list of
expected events was therefore classed as an unexpected event. From
January 2017, the reporting of AEs was altered, in that events in the
mother related to the birth of a baby or the process of birth were no
longer classed as AEs or reported within the trial.
Statistical analysis
LBR was defined as the proportion of women achieving at least one
live birth, with the number of women randomised as the denominator.
A 30% control LBR was assumed based on data from the Human
Fertilisation and Embryology Authority (HFEA). A 10% absolute in-
crease in LBR was viewed to be of sufficient clinical importance to
change practice. With continuity correction, the study required a total
of 1044 participants (522 per group) to preserve a 90% power to
detect a 10% absolute difference for a 5% two-sided test while
accounting for a 5% dropout rate. This inflated sample size accounted
for uncertainty around the assumed control LBR.
All statistical methods are detailed in a prespecified Statistical
Analysis Plan (Dimairo et al., 2020). In sum, the primary analysis was
based on intention to treat (ITT) analysis population. For the primary
outcome (live birth), the treatment effect of interest was the absolute
difference in LBRs between groups. Participants with missing data on
live birth were assumed to have not achieved a live birth (worst-case
scenario). Normal approximation to the binomial distribution was
used to calculate the 95% CI around the differences in LBRs. The as-
sociated p-value was calculated using Pearson’s chi-squared test.
Corresponding unadjusted odds ratio (OR) and unadjusted relative
risk with 95% CIs were estimated using simple logistic regression and
Binomial generalized linear model with a log link function, respectively.
Sensitivity analysis was performed by adjusting for fixed stratification
factors (site and planned treatment protocol) and potential prognostic
factors (history of pregnancy, yes or no; age; BMI; duration of infertil-
ity; smoking status, yes or no). The adjusted OR (aOR) with 95% CI
were estimated using a multiple logistic regression model and adjusted
relative risk (aRR) with 95% CI using a Binomial generalized linear
model with a log link function. The adjusted absolute difference (aAD)
in LBRs with 95% CI were postestimated via margins using the delta
method (Norton et al., 2013) after fitting a Binomial generalized linear
model with a log link function.
Further sensitivity analysis on live birth was performed assuming the
best-case scenario (that is, those with missing live birth data but
known to be pregnant were assumed to have achieved a live birth)
and using the complete case population (only those with a known live
birth outcome).
Potential heterogeneity in the effect of ES on the primary outcome
assuming the worst-case scenario was explored through prespecified
subgroup analyses via interaction tests and forest plots.
Prespecified subgroups were: day of embryo transfer (day 2, 3, 4, 5
or 6), fertilisation method (IVF, ICSI or IVF and ICSI split), treatment
protocol (long or antagonist), embryo transfer (single or double), na-
ture of embryo transferred (fresh or frozen), previous history of mis-
carriages (0–2 or 3), and cycle programming (yes or no). The aOR
with associated 95% CI and interaction p-value were estimated using a
multiple logistic regression model that included an interaction term be-
tween the treatment group and subgroup as well as fixed stratification
factors and potential prognostic factors stated above. However, for
subgroups relating to the treatment protocol and history of miscar-
riage, the planned treatment protocol and history of pregnancy covari-
ates were excluded in the model, respectively. Because of small
numbers of events and sample sizes within subgroups, the aAD with
95% CIs were not estimated as the postestimation of margins using
the delta method failed to converge.
The per protocol (PP) analysis population included women who
met all inclusion criteria as stipulated in the protocol; received the allo-
cated treatment; did not achieve a pregnancy before treatment; com-
pleted the fertility treatment cycle and successfully generated embryos;
used contraception before the ES procedure; had a fresh embryo
transfer, and were treated only using the antagonist or long protocols.
PP analysis on the primary outcome was performed assuming a worst-
case scenario using methods described for the primary ITT analysis.
Unadjusted analyses on all secondary outcomes were carried out in
the same manner as described for the primary outcome. These results
















































































































































































































































were not adjusted for multiple testing and all hypothesis tests were
performed at 5% two-sided significance level.
Analysis of safety outcomes in women and born babies was based
on randomised participants with informed consent and treatment as
received rather than allocated. Unexpected AEs and SAEs that
occurred after receiving the treatment were summarised per group
using the numbers and proportions of women who reported at least
one event as well as the total number of repeated events. The num-
bers of repeated events per woman were analysed using a Negative
Binomial regression model accounting for follow-up period to estimate
the incidence rate (IR) per treatment group and IR ratio (IRR) with
95% CI. Sensitivity analysis was performed by including all unexpected
AEs and SAEs reported at any point during the trial after randomisa-
tion. Events that occurred between receiving ES and IVF in the ES
group only were summarised descriptively. Finally, in women who
have a positive pregnancy test, safety outcomes recorded in born
babies were summarised using the numbers and proportions per
group. The unadjusted absolute differences (uADs) in proportions be-
tween groups were calculated and 95% CIs obtained using the Normal
approximation to the Binomial distribution.
All analyses were performed in Stata version 16.1 (StataCorp. 2019.




Participants were recruited between 4th July 2016 and 24th October
2018, with follow-up continuing until 24th October 2019. A total of
3454 women were identified for screening; of which 1048 (30.3%)
were randomised to either TAU (n¼ 525) or ES (n¼ 523) (Fig. 1).
The characteristics of randomised participants were very similar be-
tween groups (Table I).
Uptake of interventions and acceptability
of the ES procedure
In the ES group, 86.6% (453/523) received the ES procedure as PP
and IVF/ICSI was administered to 497 (449þ 48) 95.0% who were
randomised to ES (Supplementary Fig. S1). The median (interquartile
range: IQR) time from ES to embryo transfer was 34.0 days (26.0,
42.0) ranging from 16.0 to 346.0 (outlier) (Supplementary Fig. S2). In
total, 99.8% (448/449) viewed the ES procedure as tolerable (95% CI;
98.7%, 100.0%). The median (IQR) of pain rating scores within
30minutes of the ES procedure, at 24 hours and day 7 after the ES
procedure was 4.0 (2.0, 6.0), 1.0 (0.0, 3.0) and 0.0 (0.0, 0.0), respec-
tively (Supplementary Fig. S3 and Supplementary Table SV).
In the TAU group, 94.1% (494/525) received IVF/ICSI. Only 1.0%
(5/494) of IVF/ICSI recipients received the ES procedure outside the
trial, indicating negligible contamination. Figure 1 and Supplementary
Fig. S1 detail the reasons for not receiving allocated treatments.
Treatment cycle characteristics
The treatment cycle characteristics of women who received IVF/ICSI
were generally similar between TAU and ES groups before egg
collection, at egg collection and embryo transfer (Supplementary
Tables SVI, SVII and SVIII).
Response to IVF/ICSI treatment was high and similar between
groups, with regards to the number of eggs collected, quality of the
embryos that developed, and the proportion of patients undergoing
SET (Supplementary Tables SVII and SVIII).
Primary outcome
There was no significant difference in LBR between the groups. The
LBR was 37.1% (195/525) in the TAU and 38.6% (202/523) in the ES
groups, which gives an uAD of 1.5% (95% CI: –4.4% to 7.4%,
P¼ 0.621). This unadjusted treatment effect was consistent with sensi-
tivity analyses and very similar to adjusted results (Table II). The results
of the PP analyses also demonstrated a non-significant effect and were
similar across considered scenarios (Supplementary Table SIX). As
such, the observed effect was not statistically significant and extremely
unlikely to be of clinical importance.
We did not find strong evidence to suggest heterogeneity in the ef-
fect of ES across prespecified subgroups (Fig. 2) although a potential
for benefit could not be ruled out in women who had day 5 embryo
transfers or those who underwent cycle programming with using oral
contraception, progestogens, or oral oestrogen. However, these
results were exploratory and readers should interpret them with ex-
treme caution owing to the small numbers of participants and events
within each subgroup.
Secondary outcomes
There were no statistical differences in the rates of all secondary out-
comes between groups (Fig. 3). The clinical pregnancy rate was 40.6%
(213/525) in the TAU and 42.6% (223/523) in the ES, resulting in
only a 2.1% uAD in favour of the ES procedure (95% CI: 3.9% to
8.0%; P¼ 0.497). Supplementary Tables SX and SXI present detailed
results in ITT population and among pregnant women.
Safety outcomes
Expected AEs (Supplementary Table SXII), unexpected AEs and SAEs
(Supplementary Table SXIII) were similar between groups. Only 2.4%
(11/458) women reported unexpected AEs that occurred after the
delivery of ES but before receiving IVF/ICSI procedure (Supplementary
Table SXIV).
Successful implantation was reported in 270 and 226 women who
received TAU and ES, respectively. Three (1.1%) severe congenital ab-
normalities were reported in the TAU group only. No neonatal deaths
were reported. SAEs in born babies were comparable between groups
although we did find small reductions in low birthweight, very low
birthweight and small for gestational age in the ES compared to the
TAU group (Supplementary Table SXV).
Discussion
In this multi-centre RCT involving women undergoing IVF/ICSI for the
first time, the primary outcome was live birth for which the results
from the primary and sensitivity analyses as well as subgroup analyses



































































Figure 1. Eligibility screening and follow-up of study participants. ‡ one spontaneous pregnancy result in ectopic pregnancy;
* note the spontaneous pregnancies were followed-up; ‡ follow-up was terminated for one participant that did not commence IVF following random-
isation—follow-up was therefore terminated at the end of the follow-up phase of the trial.




































































Table I Baseline demographics and characteristics of randomised participants.
Demographic or characteristic TAU ES Total
(n5525) (n5 523) (n51048)
Fertility unit, n (%)
Birmingham 32 (6.1%) 31 (5.9%) 63 (6.0%)
Dundee 25 (4.8%) 26 (5.0%) 51 (4.9%)
Gateshead 31 (5.9%) 30 (5.7%) 61 (5.8%)
Guys & St Thomas 28 (5.3%) 27 (5.2%) 55 (5.2%)
Homerton 14 (2.7%) 15 (2.9%) 29 (2.8%)
Leeds 61 (11.6%) 61 (11.7%) 122 (11.6%)
Leicester 25 (4.8%) 26 (5.0%) 51 (4.9%)
Liverpool 54 (10.3%) 56 (10.7%) 110 (10.5%)
Manchester 62 (11.8%) 63 (12.0%) 125 (11.9%)
Newcastle 28 (5.3%) 28 (5.4%) 56 (5.3%)
Nottingham 3 (0.6%) 3 (0.6%) 6 (0.6%)
Oxford 27 (5.1%) 26 (5.0%) 53 (5.1%)
Sheffield 78 (14.9%) 75 (14.3%) 153 (14.6%)
South Tees 15 (2.9%) 15 (2.9%) 30 (2.9%)
Southampton 28 (5.3%) 29 (5.5%) 57 (5.4%)
Wrightington 14 (2.7%) 12 (2.3%) 26 (2.5%)
BMI (kg/m2) (n¼ 525) (n¼ 523) (n¼ 1048)
Mean(SD) 24.5 (3.4) 24.5 (3.3) 24.5 (3.3)
Min, max 17.3, 35.0 16.8, 34.9 16.8, 35.0
Expected age at egg collection (years) (n¼ 525) (n¼ 523) (n¼ 1048)
Mean(SD) 32.4 (3.4) 32.6 (3.4) 32.5 (3.4)
Min, max 21.5, 38.0 21.4, 38.1 21.4, 38.1
Actual age at egg collection (years) ‡ (n¼ 482) (n¼ 481) (n¼ 963)
Mean(SD) 32.4 (3.4) 32.7 (3.3) 32.5 (3.4)
Min, max 21.4, 38.8 21.4, 38.1 21.4, 38.8
Ethnicity, n (%)
White (a) 472 (89.9%) 460 (88.0%) 932 (88.9%)
Asian/Asian British (b) 31 (5.9%) 47 (9.0%) 78 (7.4%)
Mixed/multiple ethnic groups (c) 7 (1.3%) 9 (1.7%) 16 (1.5%)
Black/African/Caribbean/Black British (d) 7 (1.3%) 3 (0.6%) 10 (1.0%)
Other ethnic group (e) 5 (1.0%) 4 (0.8%) 9 (0.9%)
Prefer not to say 2 (0.4%) 0 (0.0%) 2 (0.2%)
Unknown 1 (0.2%) 0 (0.0%) 1 (0.1%)
Current cigarettes smoker (f), n(%) 13 (2.5%) 11 (2.1%) 24 (2.3%)
Number of cigarettes per day (n¼ 13) (n¼ 10) (n¼ 23)
Mean(SD) 6.2 (5.5) 8.2 (5.6) 7.1 (5.5)
Median(IQR) 3.0 (2.0, 10.0) 10.0 (2.0, 10.0) 7.0 (2.0, 10.0)
Min, max 1.0, 17.0 1.0, 20.0 1.0, 20.0
Alcohol drinker, n(%) 286 (54.5%) 278 (53.2%) 564 (53.8%)
Alcohol intake (units per week) ‡ (n¼ 279) (n¼ 274) (n¼ 553)
Mean(SD) 4.4 (3.2) 4.6 (4.1) 4.5 (3.7)
Median(IQR) 4.0 (2.0, 6.0) 3.0 (2.0, 6.0) 4.0 (2.0, 6.0)
Min, max 1.0, 18.0 1.0, 20.0 1.0, 20.0
Current recreational drug user, n(%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
History of fertility treatment (not IVF), n(%) 89 (17.0%) 109 (20.8%) 198 (18.9%)
(continued)





































































Demographic or characteristic TAU ES Total
(n5525) (n5 523) (n51048)
Fertility treatment received, n(%) (n¼ 89) (n¼ 109) (n¼ 198)
IUI 55 (61.8%) 66 (60.6%) 121 (61.1%)
Clomid 31 (34.8%) 40 (36.7%) 71 (35.9%)
IUI and Clomid 0 (0.0%) 2 (1.8%) 2 (1.0%)
Donor insemination 1 (1.1%) 1 (0.9%) 2 (1.0%)
Tamoxifen and dostinex 1 (1.1%) 0 (0.0%) 1 (0.5%)
Had other significant medical conditions, n(%) 139 (26.5%) 122 (23.3%) 261 (24.9%)
History of any previous pregnancies 150 (28.6%) 155 (29.6%) 305 (29.1%)
Planned method of fertilisation, n(%)
IVF 319 (60.8%) 316 (60.4%) 635 (60.6%)
ICSI 206 (39.2%) 207 (39.6%) 413 (39.4%)
Planned treatment protocol, n(%)
Antagonist 313 (59.6%) 308 (58.9%) 621 (59.3%)
Long protocol 212 (40.4%) 215 (41.1%) 427 (40.7%)
Planned cycle programming, n(%) 131/313 (41.9%) 126/308 (40.9%) 257/621 (41.4%)
Cycle programming details (n¼ 131) (n¼ 126) (n¼ 257)
Oral contraception 70 (53.4%) 67 (53.2%) 137 (53.3%)
Progestogens 54 (41.2%) 52 (41.3%) 106 (41.2%)
Oral oestrogen 7 (5.3%) 7 (5.6%) 14 (5.4%)
Duration of infertility (years) ‡‡ (n¼ 525) (n¼ 523) (n¼ 1048)
Mean(SD) 3.1 (1.7) 3.1 (1.9) 3.1 (1.8)
Median(IQR) 2.8 (2.0, 3.7) 2.8 (2.0, 3.5) 2.8 (2.0, 3.5)
Min, max 0.0, 15.0 0.0, 18.0 0.0, 18.0
Previous pregnancies (g), n(%)
0 375 (71.4%) 368 (70.4%) 743 (70.9%)
1 103 (19.6%) 109 (20.8%) 212 (20.2%)
2 34 (6.5%) 33 (6.3%) 67 (6.4%)
3 10 (1.9%) 4 (0.8%) 14 (1.3%)
4 2 (0.4%) 5 (1.0%) 7 (0.7%)
5 1 (0.2%) 4 (0.8%) 5 (0.5%)
Previous miscarriages, n(%)
0 442 (84.2%) 437 (83.6%) 879 (83.9%)
1 65 (12.4%) 68 (13.0%) 133 (12.7%)
2 12 (2.3%) 12 (2.3%) 24 (2.3%)
3 6 (1.1%) 6 (1.1%) 12 (1.1%)
Previous terminations, n(%)
0 479 (91.2%) 471 (90.1%) 950 (90.6%)
1 41 (7.8%) 48 (9.2%) 89 (8.5%)
2 5 (1.0%) 4 (0.8%) 9 (0.9%)
Previous stillbirths, n(%)
0 522 (99.4%) 520 (99.4%) 1042 (99.4%)
1 3 (0.6%) 3 (0.6%) 6 (0.6%)
Previous live births, n(%)
0 501 (95.4%) 497 (95.0%) 998 (95.2%)
1 21 (4.0%) 22 (4.2%) 43 (4.1%)
2 3 (0.6%) 4 (0.8%) 7 (0.7%)
(continued)
































































































































consistently failed to show evidence for benefit of ES. Results were
also consistent regarding secondary outcomes.
The major strength of this study is the specific focus on one particu-
lar population to minimise heterogeneity. We excluded patients with
potential factors that could influence endometrial quality (anovulation,
BMI >35kg/m2 and severe endometriosis). External validity was main-
tained by recruiting participants from both National Health Service and
private fertility units across the UK, including both long and antagonist
protocols, and by allowing pragmatic delivery of ES. The study met its
target sample size, with adequate power to detect a 10% difference
between groups, which we considered to be sufficient to change clini-
cal practice.
The potential confounding effect of embryo quality was addressed
by including only good responders who were likely to have a SET.
Indeed, our results show that most of participants responded well
to stimulation and approximately 80% received a SET on day 5.
However, 18% of participants still received a double embryo trans-
fer (DET). The trial was conducted across 16 centres in the UK and
therefore is a relatively accurate reflection of the national rate of
SET versus DET during the study period and is consistent with
recent HFEA data that report a 21% rate of DET across all cycles in
those under 35 years of age in 2018 (HFEA, 2020). In our trial, the
reasons for DET were identified as patient choice or the number
and/or quality of the embryos not meeting the centres’ criteria for
SET. Most participants, however, were indeed good responders
who received a SET and therefore the effect of poor embryo
quality and the replacement of more than one embryo when clini-
cally indicated is unlikely to have introduced heterogeneity in our
population.
The study did not include a sham procedure in the control group.
However, we do not believe that this would have influenced our
results as objective fertility outcomes such as those used in this study
are unlikely to be influenced by a placebo effect. Only 1% of those al-
located to the control arm received the scratch outside the study (i.e.
the participant sought ES out owing to their desire to receive the pro-
cedure) indicating high compliance and negligible contamination of the
control group.
Despite a lack of good evidence of benefit to support its use, some
in the medical community have been quick to adopt ES, including for
those undergoing their first IVF cycle (Lensen et al., 2016). Several
............................................................................................................................................................................................................................
Table I Continued
Demographic or characteristic TAU ES Total
(n5525) (n5 523) (n51048)
Previous ectopic pregnancies, n(%)
0 508 (96.8%) 504 (96.4%) 1012 (96.6%)
1 13 (2.5%) 13 (2.5%) 26 (2.5%)
2 4 (0.8%) 6 (1.1%) 10 (1.0%)
Parity, n(%) †
0 501 (95.4%) 498 (95.2%) 999 (95.3%)
1 21 (4.0%) 22 (4.2%) 43 (4.1%)
2 3 (0.6%) 3 (0.6%) 6 (0.6%)
TAU, treatment as usual; ES, endometrial scratch. ‡ Only in women with successful egg collection. Ethnicity classification: (a) English/Welsh/Scottish/Northern Irish/British, Irish,
Gypsy or Irish Traveller, and any other White background; (b) Indian, Pakistani, Bangladeshi, Chinese, and any other Asian background; (c) White and Black Caribbean, White and
Black African, White and Asian, and any other mixed/multiple ethnic groups background; (d) African, Caribbean, and any other Black/African/Caribbean/Black British background;
(e) Arab, and any other ethnic group. ‡ A few alcohol drinkers had missing alcohol intake data. ‡‡ 12 had zero duration of infertility (these were women seeking treatment or couples
in same-sex relationships without any known fertility problems). Parity is defined as the number of times a woman gave birth to a foetus (either a live or stillbirth) with a gestational age
of at least 24weeks; † parity could not be ascertained in eight births or stillbirths without gestational age: TAU (n¼ 3) and ES (n¼ 5). Preterm delivery is defined as a live birth after
24weeks but before 37 gestational age (24 and <37). Current smoker relates to smoking cigarettes and not vaping.
............................................................................................................................................................................................................................
Table II The effect of ES on achieving a live birth (primary outcome).
Primary outcome TAU n/N (%) ES n/N (%) Unadjusted treatment effect (95% CI) P-value
Absolute difference Odds ratio Relative risk
LBR (worst-case) 195/525 (37.1%) 202/523 (38.6%) 1.5% (4.4%, 7.4%) 1.06 (0.83, 1.37) 1.04 (0.89, 1.21) 0.621
Sensitivity analysis
LBR (best-case) 197/525 (37.5%) 205/523 (39.2%) 1.7% (4.2%, 7.6%) 1.07 (0.84, 1.38) 1.04 (0.90, 1.22) 0.578
LBR (complete case) 195/523 (37.3%) 202/520 (38.8%) 1.6% (4.3%, 7.5%) 1.07 (0.83, 1.37) 1.04 (0.89, 1.22) 0.604
LBR, live birth rate; best-case scenario assumes that patients who were lost to follow-up or had unknown pregnancy outcome at the end of the trial for any reasons got pregnant and
gave live birth. The complete case includes only those women with known pregnancy and a live birth outcome at the end of the trial.

















































































































studies have been undertaken in ‘unselected’ populations and were
not specifically powered towards the first-time IVF group (Nastri
et al., 2013; Yeung et al., 2014; Eskew et al., 2019; Lensen et al.,
2019); other studies have been undertaken in women undergoing
their first IVF cycle but had relatively small sample sizes (Karimzade
et al., 2010; Yoldemir and Erenus, 2011; Liu et al., 2017). A recent
study by Lensen et al. (2019) included some participants undergoing
their first IVF cycle, but was not powered specifically on LBR for the
first IVF cycle population, and did not provide information on LBR in
this particular group. Significant heterogeneity was introduced by in-
cluding populations with different prognostic potential and a high
proportion (26%) of frozen embryo transfers. Two of the largest
RCTs to date in patients receiving first-time IVF (Mahran et al.,
2016; Maged et al., 2018) included 418 and 300 participants respec-
tively and identified significant increases in IVF success in women
that received ES, but either did not follow-up participants until deliv-
ery or, according to a recent systematic review, were at a high risk
of bias (Mahran et al., 2016; Maged et al., 2018; Vitagliano et al.,
2019).
We have identified two findings that require further clarification.
First, we describe a decreased incidence of low birthweight, very low
birthweight and small for gestational age in the ES group. To the best
of our knowledge, this is the first time such an effect has been de-
scribed, however, these results should be interpreted with extreme
caution, owing to these events being highly correlated, the small num-
bers, and the lack of adjustment for other potential confounding fac-
tors. The results of a currently ongoing individual participant data
analysis should be awaited before investigating further. Second, we
identified two prespecified subgroups where the benefit of ES could
not be ruled out (cycle programming and day 5 embryo transfer).
Figure 2. The effect of ES on achieving live birth in prespecified subgroups.











































































































































However, the number of participants within these subgroups is too
small to give reliable CIs and to allow conclusions to be draw
regarding any potential positive effect.
In conclusion, this study provides evidence that, although safe and
tolerable, ES does not significantly improve pregnancy outcomes and
should not be offered to this group of women.
Supplementary data
Supplementary data are available at Human Reproduction online.
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The data underlying this study will be shared on reasonable request to
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